390 related articles for article (PubMed ID: 17902124)
1. Resistance to combined ganciclovir and foscarnet therapy in a liver transplant recipient with possible dual-strain cytomegalovirus coinfection.
Rodriguez J; Casper K; Smallwood G; Stieber A; Fasola C; Lehneman J; Heffron T
Liver Transpl; 2007 Oct; 13(10):1396-400. PubMed ID: 17902124
[TBL] [Abstract][Full Text] [Related]
2. A randomized, controlled trial comparing ganciclovir to ganciclovir plus foscarnet (each at half dose) for preemptive therapy of cytomegalovirus infection in transplant recipients.
Mattes FM; Hainsworth EG; Geretti AM; Nebbia G; Prentice G; Potter M; Burroughs AK; Sweny P; Hassan-Walker AF; Okwuadi S; Sabin C; Amooty G; Brown VS; Grace SC; Emery VC; Griffiths PD
J Infect Dis; 2004 Apr; 189(8):1355-61. PubMed ID: 15073671
[TBL] [Abstract][Full Text] [Related]
3. Combination antiviral therapy for ganciclovir-resistant cytomegalovirus infection in solid-organ transplant recipients.
Mylonakis E; Kallas WM; Fishman JA
Clin Infect Dis; 2002 May; 34(10):1337-41. PubMed ID: 11981729
[TBL] [Abstract][Full Text] [Related]
4. Case study: rapid emergence of a cytomegalovirus UL97 mutant in a heart-transplant recipient on pre-emptive ganciclovir therapy.
Gilbert C; LeBlanc MH; Boivin G
Herpes; 2001 Nov; 8(3):80-2. PubMed ID: 11867025
[TBL] [Abstract][Full Text] [Related]
5. Impact of targeted oral ganciclovir prophylaxis for transplant recipients of livers from cytomegalovirus-seropositive donors.
Shah T; Lai WK; Mutimer D
Transpl Infect Dis; 2005 Jun; 7(2):57-62. PubMed ID: 16150091
[TBL] [Abstract][Full Text] [Related]
6. Cytomegalovirus: occurrence, severity, and effect on graft survival in simultaneous pancreas-kidney transplantation.
Ricart MJ; Malaise J; Moreno A; Crespo M; Fernández-Cruz L;
Nephrol Dial Transplant; 2005 May; 20 Suppl 2():ii25-ii32, ii62. PubMed ID: 15814546
[TBL] [Abstract][Full Text] [Related]
7. Four dually resistant human cytomegalovirus strains from AIDS patients: single mutations in UL97 and UL54 open reading frames are responsible for ganciclovir- and foscarnet-specific resistance, respectively.
Baldanti F; Sarasini A; Silini E; Barbi M; Lazzarin A; Biron KK; Gerna G
Scand J Infect Dis Suppl; 1995; 99():103-4. PubMed ID: 8668930
[TBL] [Abstract][Full Text] [Related]
8. Extended routine polymerase chain reaction surveillance and pre-emptive antiviral therapy for cytomegalovirus after allogeneic transplantation.
Peggs KS; Preiser W; Kottaridis PD; McKeag N; Brink NS; Tedder RS; Goldstone AH; Linch DC; Mackinnon S
Br J Haematol; 2000 Dec; 111(3):782-90. PubMed ID: 11122138
[TBL] [Abstract][Full Text] [Related]
9. Randomized controlled trial of oral ganciclovir versus oral acyclovir after induction with intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in cytomegalovirus-seropositive liver transplant recipients.
Winston DJ; Busuttil RW
Transplantation; 2003 Jan; 75(2):229-33. PubMed ID: 12548129
[TBL] [Abstract][Full Text] [Related]
10. Cytomegalovirus UL97 mutations associated with ganciclovir resistance in immunocompromised patients from Argentina.
Sánchez Puch S; Ochoa C; Carballal G; Zala C; Cahn P; Brunet R; Salomón H; Videla C
J Clin Virol; 2004 Jul; 30(3):271-5. PubMed ID: 15135748
[TBL] [Abstract][Full Text] [Related]
11. [Ganciclovir-resistant cytomegalovirus infection: 2 cases with different clinical impact].
Reusser P; Hostettler B; Attehbofer R
Schweiz Med Wochenschr; 1996 Oct; 126(42):1779-84. PubMed ID: 8966510
[TBL] [Abstract][Full Text] [Related]
12. Is combination antiviral therapy for CMV superior to monotherapy?
Drew WL
J Clin Virol; 2006 Apr; 35(4):485-8. PubMed ID: 16387546
[TBL] [Abstract][Full Text] [Related]
13. Detection of CMV-DNA in peripheral blood leukocytes of liver transplant patients after ganciclovir treatment.
Loginov R; Höckerstedt K; Lautenschlager I
Arch Virol; 2003 Jul; 148(7):1269-74. PubMed ID: 12827460
[TBL] [Abstract][Full Text] [Related]
14. [Foscarnet therapy for ganciclovir-refractory cytomegalovirus hepatitis in a patient who underwent bone marrow transplantation from an unrelated donor].
Fujisaki T; Gondo H; Uchida N; Matsuo I; Takenaka K; Tanimoto K; Otsuka T; Minematsu T; Minamishima Y; Niho Y
Rinsho Ketsueki; 1997 Feb; 38(2):142-5. PubMed ID: 9059069
[TBL] [Abstract][Full Text] [Related]
15. Human beta-herpesvirus interactions in solid organ transplant recipients.
Mendez JC; Dockrell DH; Espy MJ; Smith TF; Wilson JA; Harmsen WS; Ilstrup D; Paya CV
J Infect Dis; 2001 Jan; 183(2):179-184. PubMed ID: 11120923
[TBL] [Abstract][Full Text] [Related]
16. Use of leflunomide in an allogeneic bone marrow transplant recipient with refractory cytomegalovirus infection.
Avery RK; Bolwell BJ; Yen-Lieberman B; Lurain N; Waldman WJ; Longworth DL; Taege AJ; Mossad SB; Kohn D; Long JR; Curtis J; Kalaycio M; Pohlman B; Williams JW
Bone Marrow Transplant; 2004 Dec; 34(12):1071-5. PubMed ID: 15489872
[TBL] [Abstract][Full Text] [Related]
17. Emergence of multiple cytomegalovirus strains in blood and lung of lung transplant recipients.
Puchhammer-Stöckl E; Görzer I; Zoufaly A; Jaksch P; Bauer CC; Klepetko W; Popow-Kraupp T
Transplantation; 2006 Jan; 81(2):187-94. PubMed ID: 16436961
[TBL] [Abstract][Full Text] [Related]
18. Advances in the diagnosis, treatment, and prevention of cytomegalovirus infections after liver transplantation.
Wiesner RH; Marin E; Porayko MK; Steers JL; Krom RA; Paya CV
Gastroenterol Clin North Am; 1993 Jun; 22(2):351-66. PubMed ID: 8389735
[TBL] [Abstract][Full Text] [Related]
19. Comparison of sequential cytomegalovirus isolates in a patient with lymphoma and failing antiviral therapy.
Ducancelle A; Belloc S; Alain S; Scieux C; Malphettes M; Petit F; Brouet JC; Sanson Le Pors MJ; Mazeron MC
J Clin Virol; 2004 Apr; 29(4):241-7. PubMed ID: 15018851
[TBL] [Abstract][Full Text] [Related]
20. CMV resistance: "more complicated than we thought".
Mascolini M
J Int Assoc Physicians AIDS Care; 1996 May; 2(5):37-9. PubMed ID: 11363529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
